Cancer
A team of researchers at the Beijing Cancer Hospital has developed a novel mRNA-based therapeutic vaccine, MTS107, which has shown promising results in treating human papillomavirus (HPV)-driven cancers, including head and neck and cervical cancers. The vaccine, which encodes mutated E6/E7 antigens from HPV16/18, has been shown
Cancer
Researchers at the Peking Union Medical College Hospital have developed exosomes-incorporated biomaterials that have shown significant promise in enhancing cancer immunotherapy. These novel platforms combine the benefits of both biomaterials and exosomes, overcoming their limitations. The study, published in Nano Today, highlights the potential of these nanoplatforms to induce immunogenic
Vaccines
Researchers from Soochow University have made a significant discovery in the field of cancer vaccines, detailing a novel strategy to enhance the efficacy of immunotherapy. By developing a nanovesicle-based approach, they have found that loading tyrosine kinase inhibitors (TKIs) into these tiny vesicles can increase Major-Histocompatibility-Complex I (MHC I) expression
Vaccines
Researchers at Peking University in Beijing, China, have developed a novel approach to enhance TCR-T cell therapy and reject antigen-heterogeneous tumors. The multi-engineered T cell vaccine (Multi-Tvac) involves a combination of a TCR-targeted cognate peptide, tumor neoantigens, and an LAG-3Ig adjuvant signal, which significantly boosts dendritic cell (DC) maturation, enhances
Vaccines
Scientists at Sungkyunkwan University have made a significant breakthrough in the treatment of autoimmune diseases, specifically multiple sclerosis (MS). The research, funded by the Ministry of Science & ICT (MSIT), Republic of Korea, has led to the development of a therapeutic vaccine that effectively reduces glycolysis in MS-mediated activated immune
Vaccines
A new study published in the journal Vaccines has highlighted the need for a globally approved vaccine to combat the devastating effects of African swine fever virus (ASFV) on the global pig industry. Researchers from the China Agricultural University have made significant progress in identifying T-cell epitopes and vaccine development
Cancer
Researchers at Rutgers University - The State University of New Jersey have made significant progress in the development of fragment-based immune cell engager antibodies, which have shown promise in treating various cancers, infectious, and autoimmune diseases. According to a recent review, these antibodies have been designed to target specific proteins,
Vaccines
A new study published in the journal Vaccine has shed light on the effectiveness of Ingelvac PRRS MLV vaccines in conferring partial protection against heterologous wild type challenge of porcine reproductive and respiratory syndrome (PRRS). The research, conducted by a team of scientists at Iowa State University, utilized a combination
Biochemistry
Research conducted by a team of scientists at Fudan University has shed light on the intricacies of sepsis-induced immunoparalysis, a condition that can lead to life-threatening secondary infections and multiple organ dysfunction syndrome. The study revealed that neutrophil extracellular traps (NETs) play a crucial role in the development of immunoparalysis
Biochemistry
Researchers at the Chinese Academy of Medical Sciences have made a significant breakthrough in the field of immunotherapy by developing engineered T-cells that can enhance the interaction between T-cells and dendritic cells. According to a report published in Cell Reports Medicine, this new strategy has shown promising results in treating
Cancer
Recent research at Middle East University in Amman, Jordan, has elucidated the multifunctional role of short-chain fatty acids (SCFAs) in T lymphocyte biology, highlighting their therapeutic potential in cancer, infection, and autoimmune diseases. SCFAs, including acetate, propionate, and butyrate, have significant functions in host immune modulation, particularly in regulating T-cell
Cancer
Researchers at the Indiana University School of Medicine have made a significant breakthrough in cancer treatment by reprogramming regulatory T cells (Tregs) to enhance antitumor immunity. According to a study published in Science Immunology, shifting the expression of FOXP3 from its full-length isoform to a short isoform with exon 2
